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PLoS BIOLOGY

Genetic Deficiency of Glycogen Synthase
Kinase-3b Corrects Diabetes in Mouse Models
of Insulin Resistance
Katsuya Tanabe1, Zhonghao Liu1, Satish Patel2, Bradley W. Doble2, Lin Li1, Corentin Cras-Méneur1, Sara C. Martinez1,
Cris M. Welling1, Morris F. White3, Ernesto Bernal-Mizrachi1, James R. Woodgett2, M. Alan Permutt1*
1 Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis, Missouri, United States of America, 2 Samuel Lunenfeld
Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, 3 Howard Hughes Medical Institute, Children’s Hospital, Harvard Medical School, Boston, Massachusetts,
United States of America

Despite treatment with agents that enhance b-cell function and insulin action, reduction in b-cell mass is relentless in
patients with insulin resistance and type 2 diabetes mellitus. Insulin resistance is characterized by impaired signaling
through the insulin/insulin receptor/insulin receptor substrate/PI-3K/Akt pathway, leading to elevation of negatively
regulated substrates such as glycogen synthase kinase-3b (Gsk-3b). When elevated, this enzyme has antiproliferative
and proapoptotic properties. In these studies, we designed experiments to determine the contribution of Gsk-3b to
regulation of b-cell mass in two mouse models of insulin resistance. Mice lacking one allele of the insulin receptor (Irþ/)
exhibit insulin resistance and a doubling of b-cell mass. Crossing these mice with those having haploinsufficiency for
Gsk-3b (Gsk-3bþ/) reduced insulin resistance by augmenting whole-body glucose disposal, and significantly reduced bcell mass. In the second model, mice missing two alleles of the insulin receptor substrate 2 (Irs2/), like the Irþ/ mice, are
insulin resistant, but develop profound b-cell loss, resulting in early diabetes. We found that islets from these mice had a
4-fold elevation of Gsk-3b activity associated with a marked reduction of b-cell proliferation and increased apoptosis.
Irs2/ mice crossed with Gsk-3bþ/ mice preserved b-cell mass by reversing the negative effects on proliferation and
apoptosis, preventing onset of diabetes. Previous studies had shown that islets of Irs2/ mice had increased cyclindependent kinase inhibitor p27kip1 that was limiting for b-cell replication, and reduced Pdx1 levels associated with
increased cell death. Preservation of b-cell mass in Gsk-3bþ/Irs2/ mice was accompanied by suppressed p27kip1 levels
and increased Pdx1 levels. To separate peripheral versus b-cell–specific effects of reduction of Gsk3b activity on
preservation of b-cell mass, mice homozygous for a floxed Gsk-3b allele (Gsk-3F/F) were then crossed with rat insulin
promoter-Cre (RIP-Cre) mice to produce b-cell–specific knockout of Gsk-3b (bGsk-3b/). Like Gsk-3bþ/ mice, bGsk-3b/
mice also prevented the diabetes of the Irs2/ mice. The results of these studies now define a new, negatively regulated
substrate of the insulin signaling pathway specifically within b-cells that when elevated, can impair replication and
increase apoptosis, resulting in loss of b-cells and diabetes. These results thus form the rationale for developing agents
to inhibit this enzyme in obese insulin-resistant individuals to preserve b-cells and prevent diabetes onset.
Citation: Tanabe K, Liu Z, Patel S, Doble BW, Li L, et al. (2008) Genetic deficiency of glycogen synthase kinase-3b corrects diabetes in mouse models of insulin resistance. PLoS
Biol 6(2): e37. doi:10.1371/journal.pbio.0060037

[13,14], illustrating the potential importance of this pathway
for expanding b-cells in patients and perhaps resisting the
apoptosis that accompanies long-standing diabetes. Knowing
that increased expression of Akt in b-cells leads to marked
expansion, these results have focused interest on the role of
two negatively regulated Akt substrates, FoxO1 and Gsk-3b,
each known to regulate carbohydrate and lipid metabolism in
insulin target tissues while also exhibiting antiproliferative

Introduction
Despite treatment with agents that enhance b-cell function
and insulin action, reduction in b-cell mass is relentless in type
2 diabetes (T2DM) [1–4]. Why b-cells fail in some individuals is
a central issue in diabetes research today. The molecular
mechanisms enabling b-cell adaptation to insulin resistance
are being discovered primarily in animal models [5–7].
Important genetic models have focused on the requirement
for insulin signaling through b-cell insulin/insulin-like growth
factor 1 (IGF1) receptors (reviewed in [8,9]). Whereas mice
with total-body deﬁciency for insulin receptor substrate 1
(Irs1/) have insulin resistance and signiﬁcant expansion of bcell mass, insulin receptor substrate 2–deﬁcient mice (Irs2/)
have insulin resistance yet develop postnatal b-cell loss and
severe diabetes (reviewed in [10]). In this model and in others,
the primacy of PI-3K/Akt activity in expansion and postnatal
maintenance of b-cell mass was apparent (reviewed in [11,12]).
The remarkable ability of b-cell mass to expand via enhanced
proliferation and reduced apoptosis was demonstrated in
transgenic mice expressing constitutively active Akt in b-cells
PLoS Biology | www.plosbiology.org
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that in Irþ/ mice, increased Gsk-3b as well as FoxO1 activity
could be contributing to the insulin-resistant phenotype. We
crossed Irþ/ mice with mice lacking one allele of Gsk-3b (Gsk3bþ/) and found that Gsk-3bþ/Irþ/ mice, like Foxo1þ/Irþ/ mice,
also had improved insulin sensitivity and reduced b-cell mass.
Next, we investigated a mouse that is missing two alleles of the
insulin receptor substrate 2 (Irs2/), that is also insulin
resistant, but develops profound b-cell destruction resulting
in marked diabetes [38]. Although crossing Irs2/ mice with
Foxo1þ/ mice increased b-cell mass and proliferation [39],
suggesting that increased b-cell FoxO1 activity was contributing to b-cell loss in Irs2/ mice, we found that Gsk-3b activity
in islets of Irs2/ mice was also markedly elevated. We
determined that Gsk-3bþ/Irs2/ mice had reduced, but
persistent, insulin resistance, yet do not develop diabetes, as
a result of maintaining islet b-cell mass. Preservation of b-cell
mass in Gsk-3bþ/Irs2/ mice appeared to be due to accelerated
proliferation and decreased apoptosis of b-cells. Reduction of
Gsk-3b, like reduction of FoxO1, results in preservation of bcell mass and rescues the diabetes in this model. The results of
these studies now deﬁne a new, negatively regulated substrate
of the insulin signaling pathway speciﬁcally within b-cells that
when elevated, can impair replication and increase apoptosis,
resulting in loss of b-cells and diabetes.

Author Summary
Diabetes is often characterized by a failure of insulin production by
pancreatic b-cells to properly regulate glucose homeostasis. Insulin
resistance can lead to b-cell failure, and our studies have focused on
elucidating the mechanisms involved in this postnatal failure. In this
study, we evaluated a new, negatively regulated enzyme of the
insulin signaling pathway, glycogen synthase kinase 3 (Gsk-3),
specifically within insulin-producing pancreatic b-cells. When this
enzyme is elevated, it can impair replication and increase cell death,
resulting in loss of insulin-producing cells and diabetes. Gsk-3 is also
known to regulate cell death and proliferation in neurons. We
assessed the role of Gsk-3 on glucose homeostasis in two different
mouse models of insulin resistance. We demonstrated that
genetically reducing the levels of Gsk-3b in the insulin-resistant
mouse improved glucose homeostasis. In another model in which
severe insulin resistance is associated with destruction of b-cells,
reducing Gsk-3b not only preserved b-cells by increasing proliferation and reducing cell death, but it also corrected diabetes.
Controlling activity of Gsk-3 could lead to new hopes for
maintaining or improving b-cell number and prevention of diabetes.

and proapoptotic properties when expressed at high levels
[15,16]. There is substantial evidence, mostly from overexpression of a constitutively nuclear FoxO1, that FoxO1 has
detrimental effects on b-cell proliferation and survival [17].
On the other hand, there is little known about the effects of
expression of Gsk-3b on b-cell proliferation and/or survival.
Glycogen synthase kinase-3 (Gsk-3) was originally identiﬁed
as a serine/threonine kinase that inactivates glycogen synthase
[18]. Early studies showed that insulin inhibits Gsk-3 activity
through PI-3K/Akt-induced phosphorylation promoting glycogen synthesis and glucose disposal [19–22]. Later, the
enzyme was shown to affect many cellular processes, including transcription, translation, cell cycle regulation, and
apoptosis [16,23–27]. Mammals express two isoforms, Gsk-3a
and Gsk-3b, which share similar kinase domains but differ
considerably in their termini. Inactivation of Gsk-3b appears
to be the major route by which insulin activates glycogen
synthesis [22,28], and recent studies have demonstrated that
elimination of Gsk-3b is more effective at promoting neuronal survival than is elimination of Gsk-3a [29].
Gsk-3 activity has been shown to be increased in peripheral
tissues in diabetic animals and patients [30–32], and diabetes
was reversed in obese diabetic mice treated with Gsk-3
inhibitors [33–35]. Because inhibitors have differing degrees
of kinase speciﬁcity, Gsk-3–deﬁcient genetic models were
created. Disruption of the Gsk-3b gene in mice results in
embryonic lethality [23], yet mice with loss of one allele (Gsk3bþ/) are viable and express reduced levels of protein and
enzymatic activity [23]. Although Gsk-3bþ/ mice have been
little studied, they have been shown to have behavioral effects
similar to lithium-treated mice, suggesting that Gsk-3b is the
main determinant of Gsk-3 activity in the nervous system [36].
The availability of these Gsk-3bþ/ mice provided the
opportunity to assess the role of Gsk-3b on insulin sensitivity
and pancreatic b-cell function.
Mice haploinsufﬁcient for the insulin receptor (Irþ/) have
insulin resistance with expanded islet b-cell mass and hyperinsulinemia [37]. Crossing Irþ/ mice with mice haploinsufﬁcient for FoxO1 (Foxo1þ/) improved insulin sensitivity and
reduced islet mass [17]. In the current study, we hypothesized
PLoS Biology | www.plosbiology.org

Results
Gsk-3b Deficiency (Gsk-3bþ/) Promotes Insulin Sensitivity
and Reduces the Hyperinsulinemia of Insulin Receptor–
Deficient Mice (Irþ/)
To determine whether Gsk-3b is a downstream contributor
to the insulin resistance of insulin receptor–deﬁcient mice,
Gsk-3bþ/ mice were crossed with mice missing one allele of the
insulin receptor (Irþ/), previously shown to have insulin
resistance and elevation of insulin levels in adult animals
[37]. Fasting and fed glucose and insulin levels were assessed in
Gsk-3bþ/, Irþ/, and compound heterozygous (Gsk-3bþ/Irþ/)
mice and compared to levels in wild type (WT) at 26 wk of age
(Figure 1A). Both fasting and fed insulin levels were signiﬁcantly reduced in mice lacking one allele of Gsk-3b, thus
indicating that genetic deﬁciency of Gsk-3b activity improves
insulin sensitivity. In Irþ/ mice, both fasting and fed insulin
levels were higher than in WT mice, consistent with previous
reports [37]. In compound heterozygous Gsk-3bþ/Irþ/ mice,
the serum insulin values were signiﬁcantly decreased relative
to those in Irþ/ mice in both the fasting and the fed state,
although the values were signiﬁcantly elevated relative to that
in Gsk-3bþ/ mice (p , 0.05), suggesting that Gsk-3bþ/Irþ/ mice
are still insulin resistant. Similar differences in glucose and
insulin values were observed in mice at 8–10 wk of age (Figure
S1A and S1B). Gsk-3bþ/Irþ/ mice were found to exhibit
improved glucose tolerance relative to that in Irþ/ mice
(Figure S1C). The results of these experiments thus indicate
that (1) endogenous Gsk-3b activity contributes to ambient
insulin sensitivity, and (2) that Gsk-3b activity is a downstream
mediator of the insulin resistance of the Irþ/ mice.

Gsk-3bþ/Irþ/ Mice Exhibit Enhanced Peripheral InsulinMediated Glucose Disposal and Reduced b-Cell Mass
Relative to Irþ/ Mice
To further characterize the apparent improvement of
insulin sensitivity, hyperinsulinemic-euglycemic clamps were
0308
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Figure 1. Glucose and Insulin Values in Wild Type (WT), Gsk-3bþ/, Irþ/, or Gsk-3bþ/Irþ/ Mice and Hyperinsulinemic-Euglycemic Clamp in Male Irþ/ and
Gsk-3bþ/Irþ/ Mice
Fasting and fed glucose and insulin values in male mice either WT (n  6), haploinsufficient for Gsk-3b (Gsk-3bþ/; n  6) or the insulin receptor (Irþ/;
n  6), or combined (Gsk-3bþ/Irþ/; n  6), as indicated.
(A) Fasting and fed glucose (26 wk of age).
(B) Fasting and fed insulin (26 wk of age).
(C) Glucose disposal rate (mg/kg/min).
(D) Glucose infusion rate (mg/kg/min).
(E) Hepatic glucose output (mg/kg/min) determined on fasted, conscious 28-wk-old mice of indicated genotypes using the hyperinsulinemiceuglycemic clamp (n ¼ 4 per each genotype).
Results are presented as the mean values 6 S.E.M. in the graph. A single asterisk (*) indicates p , 0.05.
doi:10.1371/journal.pbio.0060037.g001

Pancreatic sections with insulin staining of each of the four
genotypes are shown in Figures 2A–2D. Akthough there were
no differences in pancreatic areas (unpublished data), the bcell mass was increased in Irþ/ mice as previously noted [37],
and reduced in Gsk-3bþ/Irþ/ mice as assessed by pancreatic
morphometry (Figure 2E). In conclusion, mice missing one
allele of Gsk-3b when crossed with Irþ/ mice had reduced
hyperinsulinemia associated with reduced b-cell mass.

performed. The rates of glucose disposal and glucose infusion
were increased in Gsk-3bþ/Irþ/ mice relative to those in Irþ/
mice, conﬁrming enhanced insulin sensitivity (Figure 1C and
1D). Hepatic glucose production did not appear to differ
between Irþ/ mice and Gsk-3bþ/Irþ/ mice (Figure 1E),
suggesting that the beneﬁcial effects of genetic reduction of
Gsk-3b on carbohydrate metabolism were a result of
enhanced effects on peripheral insulin-mediated glucose
disposal. These results are consistent with those of Patel et
al. (S. Patel, B. W. Doble, K. MacAulay, E. M. Sinclair, D. J.
Drucker, and J. R. Woodgett, unpublished data) in which
tissue-speciﬁc knockout of Gsk-3b in skeletal muscle improved insulin sensitivity, whereas elimination of the gene in
liver had no apparent effect on carbohydrate metabolism.
PLoS Biology | www.plosbiology.org

Gsk-3b Is Activated in Islets of the Irs2-Deficient (Irs2/)
Mice
Whereas the Irþ/ mice have peripheral insulin resistance,
Irs2-deﬁcient mice (Irs2/) have both peripheral insulin
resistance as well as impaired insulin signaling, as measured
0309
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Figure 2. b-Cell Mass in WT, Gsk-3bþ/, Irþ/, or Gsk-3bþ/Irþ/
(A–D) Pancreatic sections from 10-mo-old mice of the indicated genotypes were stained with antibodies to insulin and then were counterstained with
hematoxylin. Scale bar represents 100 lm.
(E) Random sections of the entire pancreas from 10-mo-old mice of the indicated genotypes were stained with hematoxylin and were measured
to determine the b-cell mass (WT: n ¼ 3, Gsk-3bþ/: n ¼ 3, Irþ/: n ¼ 4, and Gsk-3bþ/Irþ/: n ¼ 4). Results are expressed as b-cell mass (mg). All values are
represented as the mean 6 S.E.M. A single asterisk (*) indicates p , 0.05.
doi:10.1371/journal.pbio.0060037.g002

(Figure 3D). Irs2/ mice developed a progressive increase
with severe hyperglycemia, mean glucose .500 mg/dl, at 12
wk of age, conﬁrming previous observations [38]. In contrast,
blood glucose concentrations in Gsk-3bþ/Irs2/ mice were
signiﬁcantly reduced relative to that in Irs2/ mice, although
plasma insulin did not differ (Figure 3E). Fasting glucose
levels at 6 wk of age did not differ, but did at 8 wk (Table S1).
To interpret the basis for plasma insulin levels, insulin
sensitivity was examined in Irs2/ and Gsk-3bþ/Irs2/ mice
relative to that in WT mice by insulin tolerance testing in 6wk-old mice (Figure 3E). Interestingly, the Gsk-3bþ/Irs2/
mice maintained insulin resistance relative to that in WT
mice, suggesting that the beneﬁcial effects of genetic
deﬁciency of Gsk-3b on restoration of glucose homeostasis
is not solely due to altered insulin sensitivity.

by reduced Akt activity in islets [40]. Because Akt is a negative
regulator of Gsk-3b activity and Gsk-3b is a known regulator of
both proliferation and apoptosis [16], we hypothesized that
increased Gsk-3b activity could also contribute to the reduced
b-cell mass of Irs2/ mice. Islets from Irs2/ mice were
examined at 6 wk of age and shown to have decreased
phosphorylation at serine 473 of Akt and phosphorylation at
serine 9 of Gsk-3b in Irs2/ compared with WT mice (Figure
3A). Additionally, islets from Irs2/ mice were found to have a 4fold elevation of phosphorylated glycogen synthase, a substrate
of Gsk-3b and a measure of its increased activity (Figure 3B).

Gsk-3b Haplodeficiency in Irs2/ Mice Corrects Diabetes
Because of the antiproliferative and proapoptotic effects of
Gsk-3b activity in other tissues [16], ﬁnding increased Gsk-3b
activity in islets from Irs2/ mice was consistent with the
possibility that this may contribute to the decreased b-cell
mass and function of these mice. We therefore crossed mice
haploinsufﬁcient for Gsk-3b with Irs2/ mice to determine
whether it would have beneﬁcial effects on preserving b-cell
mass and prevent diabetes. We generated double knockout
mice (Gsk-3bþ/Irs2/) by interbreeding Gsk-3bþ/ and Irs2þ/
mice. The Irs2/ mice gained weight until about 9 wk, when
body weight plateaued and began to decline. In contrast, the
Gsk-3bþ/Irs2/ mice continued to increase body weight,
indistinguishable from that of the WT or Gsk-3bþ/ mice at
12 wk (Figure 3C) and at 24 wk (Figure S2A).
Fed glucoses were determined at 6, 8, 10, and 12 wk of age
PLoS Biology | www.plosbiology.org

b-Cell Mass Is Preserved in Gsk-3bþ/Irs2/ Mice
Islet morphology in mice of each genotype was assessed at 8
wk of age. Immunostaining for insulin and glucagon on
pancreatic sections are shown in Figure 4A–4F. The insulin
immunoreactive area in Irs2/ mice was severely reduced
(Figure 4B and 4E) relative to that in Gsk-3bþ/ mice, consistent
with previous reports [38,39]. In contrast, there appeared to
be preservation of b-cell mass in the Gsk-3bþ/Irs2/ mice
(Figure 4C and 4F). As quantiﬁed in Figure 4G, islet mass of
Irs2/ mice was reduced to 30% of WT and Gsk-3bþ/ mice,
whereas the mass of Gsk-3bþ/Irs2/ mice did not differ from
that of the control mice. Although the a-cell mass was not
0310
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Figure 3. Metabolic Phenotypes of Irs2/ and Gsk-3bþ/Irs2/ Mice
(A) Islets were isolated from 6-wk-old WT and Irs2/ mice, and were lysed. Lysates were subjected to western blot analysis using anti-phospho Akt (S473),
anti-phospho Gsk-3b (S9), anti-total Gsk-3b, anti-phosho glycogen synthase, anti-total Akt, and b-actin. One of four independent experiments is shown.
(B) Densitometry of phospho-Gsk-3b (S9) and phospho-glycogen synthase was measured and normalized over total Gsk-3b and b-actin, respectively.
Mean phosphorylation 6 S.E.M. is represented in the graph.
(C) Body weights at indicated age (WT: n ¼ 12, Gsk-3bþ/: n ¼ 12, Irs2/: n ¼ 29, and Gsk-3bþ/Irs2/: n ¼ 14).
(D) Fed glucose concentration in blood derived from mouse tail vein at indicated age. (WT: n ¼ 12, Gsk-3bþ/: n ¼ 12, Irs2/: n ¼ 29, and Gsk-3bþ/Irs2/:
n ¼ 14).
(E) Fasting and fed plasma insulin levels at 8 wk of age and fed insulin levels at 12 wk of age in mice either WT (n ¼ 10), Gsk-3bþ/ (n ¼ 9), Irs2/ (n ¼ 15),
or Gsk-3bþ/Irs2/ (n ¼ 12) were determined.
(F) Insulin tolerance tests were performed on 4-h fasted male WT (n ¼ 4), Irs2/ (n ¼ 6), and Gsk-3bþ/Irs2/ (n ¼ 4) mice at 6 wk of age. Glucose levels
were assessed at the indicated time intervals after intraperitoneal injection of human regular insulin (0.5 U/kg). Results are presented as the mean 6
S.E.M. in the graph.
A single asterisk (*) indicates p , 0.05; double asterisks (**) indicate p , 0.01; and triple asterisks (***) indicate p , 0.001.
doi:10.1371/journal.pbio.0060037.g003

the Gsk-3bþ/Irs2/ mice relative to that in the Irs2/ mice
could be due to increased proliferation or reduced apoptosis
or both. We measured Ki67-positive cells in b-cells to assess
proliferation in Irs2/ and Gsk-3bþ/Irs2/ mice, as shown in
Figure 5A. The percent of Ki67-positive b-cells in Irs2/ mice
was markedly reduced compared to that in WT and Gsk-3bþ/
mice at 8 wk of age (Figure 5B). Remarkably, the percentage
of Ki67-positive cells in Gsk-3bþ/Irs2/ mice was over four

determined, the reduction in b- to a-cell ratio (Figure 4H) was
consistent with the reduction in b-cell mass.

b-Cell Proliferation Is Maintained and Apoptosis Reduced
in Islets of Gsk-3bþ/Irs2/ Mice
The progressive loss of b-cell mass in Irs2/ mice has been
shown to be associated with reduced proliferation and
increased apoptosis [38–41]. Preservation of b-cell mass in
PLoS Biology | www.plosbiology.org
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Figure 4. Morphologic Phenotypes of Irs2/ and Gsk-3bþ/Irs2/ Mice
(A–C) Pancreatic sections from 8-wk-old mice of the indicated genotypes were stained with antibodies to insulin and then were counterstained with
hematoxylin. Scale bar represents 100 lm.
(D–F) Pancreatic sections from 8-wk-old mice of the indicated genotypes at 8 wk were stained with antibodies to insulin (red) and glucagon (green).
Scale bar represents 50 lm.
(G) Random sections of the entire pancreas from 8-wk-old mice of the indicated genotypes were stained with hematoxylin and were measured to
determine the b-cell area and quantification of the b cell mass. Results are expressed as the mg of total weight containing insulin-immunoreactive cells.
(WT: n ¼ 3, Gsk-3bþ/: n ¼ 4, Irs2/: n ¼ 6, and Gsk-3bþ/Irs2/: n ¼ 5).
(H) Quantification of the b/a cell ratio is shown. (WT: n ¼ 3, Gsk-3bþ/: n ¼ 4, Irs2/: n ¼ 5, and Gsk-3bþ/Irs2/: n ¼ 5).
Results are expressed as the mean 6 S.E.M.. A single asterisk (*) indicates p , 0.05; double asterisks (**) indicate p , 0.01; and triple asterisks (***)
indicate p , 0.001.
doi:10.1371/journal.pbio.0060037.g004

times greater than in Irs2/ mice, and even increased
approximately 2-fold relative to that in WT and Gsk-3bþ/.
We next assessed apoptosis by terminal deoxynucleotidyl
transferase-mediated dUTP-biotin nick-end labeling (TUNEL) staining in pancreatic b-cells at 8 wk of age (Figure
S3). The number of TUNEL-positive b-cells was markedly
increased in Irs2/ mice compared to that in WT and Gsk-3bþ/

mice (Figure 5C). Whereas TUNEL positivity was signiﬁcantly increased in Gsk-3bþ/Irs2/ mice relative to that in WT
and Gsk-3bþ/ mice, importantly there was approximately a
60% reduction in TUNEL-positive cells in Gsk-3bþ/Irs2/
mice compared to Irs2/ mice. These observations indicate
that the preservation of b-cell mass in Gsk-3bþ/Irs2/ mice
was associated with reversal of decreased proliferation and
increased apoptosis of Irs2/ mice.

from WT, Irs2/, and Gsk-3bþ/Irs2/ mice at 6 wk of age were
examined by western blot analysis to assess insulin signaling
upstream and downstream of Gsk-3b. Phosphorylation of Akt
was equally reduced in Irs2/ and Gsk-3bþ/Irs2/ mice
(Figure 6A), indicating that haploinsufﬁciency for Gsk-3b
did not alter the insulin signaling pathway through Akt.
Interestingly, total Gsk-3 activity remained reduced in Gsk3bþ/Irs2/, indicating that neither the intact Gsk-3b allele
nor the Gsk-3a alleles compensated to increase Gsk-3 activity.
Gsk-3bþ/Irs2/ mice had no change in Irs1 expression levels
relative to those in Irs2/ mice (Figure 6B). Loss of b-cells in
Irs2/ mice was shown to be associated with decreased islet
Pdx1 protein [39,42], whereas transgenic expression of Pdx1
rescued the diabetic phenotype [43]. Associated with preservation of b-cell mass, Gsk-3bþ/Irs2/ mice had preservation of
Pdx1 levels relative to that in Irs2/ mice by western blot
analysis (Figure 6B) and nuclear localization by immunocytochemistry (Figure 6C).
The Irs2/ mice have been shown to have increased levels

Pdx1 Levels Are Maintained and p27kip1 Levels Are
Reduced in Islets from Gsk-3bþ/Irs2/ Mice
To examine possible molecular mechanisms for the
preservation of islet b-cell mass in Gsk-3bþ/Irs2/ mice, islets
PLoS Biology | www.plosbiology.org
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islets of WT mice revealed that only some of the islet cells
were positive for p27kip1 (Figure 6D, left). In contrast,
virtually all of the nuclei of the islet cells in Irs2/ mice were
positive (Figure 6D, middle). In Gsk-3bþ/Irs2/ mice, p27kip1
could only be detected in some of the nuclei of the islet cells
(Figure 6D, right), with a staining that appears to be weaker
than observed in Irs2/ mice, consistent with the increased
proliferation observed in these mice.

b-Cell–Specific Gsk-3b Deficiency in Irs2/ Mice Corrects
Diabetes
To separate peripheral versus b-cell–speciﬁc effects of
reduction of Gsk-3b activity on preservation of b-cell mass,
mice homozygous for a ﬂoxed Gsk-3b allele (Gsk-3bF/F) were
then crossed with rat insulin 2 promoter-Cre (RIP-Cre) mice
to produce b-cell–speciﬁc knockout of Gsk-3b (bGsk-3b/). As
shown in Figure 7A, expression of islet Gsk-3b was reduced
more than 80%. bGsk-3b/Irs2/ mice also maintained
relatively normal plasma glucose compared to the severe
hyperglycemia of the Irs2/ mice for the 20 wk of observation
(Figures 7B). Additionally, the hyperinsulinemia of the Irs2/
mice was maintained in bGsk-3b/Irs2/ mice (Figure 7C).

Gsk-3 Activity Stabilizes p27kip1 in Mouse Insulinoma Cells
and in Primary Mouse Islets
To further examine effects of reduction in Gsk-3 activity on
protein stability of p27kip1, mouse insulinoma cells were
pretreated with lithium to inhibit Gsk-3 activity, and protein
levels were assayed 4 h after addition of cyclohexamide to
inhibit new protein synthesis. Lithium treatment reduced Gsk3 activity and markedly reduced levels of p27kip1 compared to
cells treated with NaCl as an osmotic control (Figure 8A).
To conﬁrm the physiological signiﬁcance of the effects of
Gsk-3 activity on p27kip1 levels, primary mouse islets were
examined. Islets were isolated from WT mice and incubated
for 4 h in serum-free medium, followed by 3 h with no
addition, or with the addition of either IGF-1 to activate the
insulin signaling pathway, with lithium, or with both, or islet
protein lysates blotted for p27kip1 levels (Figure 8B). Addition
of IGF-1 and lithium resulted in reduced p27kip1 levels, with
maximum reduction with addition of both. These results
provide physiological support for the conclusion that Gsk-3
activity stabilizes p27kip1 levels in pancreatic islets.

Figure 5. Proliferation and Apoptosis in Islets of the Irs2/ and
Gsk-3bþ/Irs2/ Mice
(A) Pancreatic sections from 8-wk-old mice of the indicated genotypes
were stained with antibodies to Ki67 (red) and insulin (green). Arrowheads indicate proliferating cells. Scale bar represents 50 lm.
(B) The number of cells that are positive for both Ki67 and insulin have
been quantified as a percentage of total number of insulin-positive cells in
the sections. (WT: n ¼ 3, Gsk-3bþ/: n ¼ 3, Irs2/: n ¼ 5, and Gsk-3bþ/Irs2/:
n ¼ 5). Results are represented as mean 6 S.E.M. Double asterisks (**)
indicate p , 0.01.
(C) Apoptotic b-cells in pancreatic sections from 8-wk-old mice of the
indicated genotypes (WT: n ¼ 4, Gsk-3bþ/: n ¼ 4, Irs2/: n ¼ 7, and Gsk3bþ/Irs2/: n ¼ 5) were assessed through TUNEL and anti-insulin
staining. The proportion of cells that are positive for both are
represented as a percentage of the total number of insulin-positive
cells in the sections. Results are represented as mean 6 S.E.M. A single
asterisk (*) indicates p , 0.05; triple asterisks (***) indicate p , 0.001.
doi:10.1371/journal.pbio.0060037.g005

Discussion
The current study offers speciﬁc genetic approaches to assess
the role of Gsk-3b in control of b-cell mass in insulin-resistant
diabetic models, and as a consequence, several novel observations were made. Loss of one allele of Gsk-3b in WT mice
promotes insulin sensitivity and in Irþ/ mice reduces insulin
resistance and improves glucose tolerance by enhancing
glucose disposal. Severely insulin-resistant Irs2/ mice were
found to have elevated islet Gsk-3 activity associated with severe
reduction of b-cell proliferation and elevated apoptosis. Loss of
one allele of Gsk-3b in Irs2/ mice reversed these ﬁndings,
preserving b-cell mass and preventing diabetes. Additionally,
Pdx1 levels were depressed and p27Kip1 levels were increased in
islets of Irs2/ mice, and they were also reversed by loss of one
allele of Gsk-3b. b-cell–speciﬁc deﬁciency of Gsk-3b reversed
the diabetes of the Irs2/ mice, indicating the importance of
Gsk-3b in islet b-cells. Finally, in vitro studies demonstrated

of the cyclin-dependent kinase inhibitor p27kip1 in b-cells,
and the loss of b-cell mass and diabetes was corrected when
these mice were placed on a p27kip1 null background [40].
This established p27kip1 as a rate-limiting determinant of
proliferation in this insulin-resistant model. Interestingly, it
was recently shown that in non–b-cells, Gsk-3b stabilizes
p27kip1 [44]. We conﬁrmed that islets of Irs2/ mice have
increased p27kip1 protein, and found that the increased
proliferation in b-cells of Gsk-3bþ/Irs2/ mice was associated
with decreased p27kip1 levels (Figure 6B). Immunostaining on
PLoS Biology | www.plosbiology.org
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Figure 6. Effects of Inhibition of Gsk-3b Activity on Pdx1 and p27kip1 Expression in Islets from Irs2/ Mice
Islets were isolated from 6 wk-old WT, Gsk-3bþ/Irs2/, and Irs2/ mice.
(A) Western blot analysis with anti-total Gsk-3, anti-phospho glycogen synthase, anti-phospho Akt (S473), anti-total Akt, and b-actin. Representative
results of four independent experiments are presented. Densitometry of phosphorylation of Akt (S473) was measured and normalized over total Akt.
Mean values 6 S.E.M. are summarized on the graph. A single asterisk (*) indicates p , 0.05.
(B) Western blot analysis with anti-total Gsk-3, anti-Irs2, anti-Irs1, anti-Pdx1, anti-p27kip1, and anti-b-actin. Representative results of four independent
experiments are presented. Densitometry of Pdx1 and p27kip1 was measured and normalized over b-actin. Mean protein levels 6 S.E.M. are summarized
on the graph. A single asterisk (*) indicates p , 0.05; double asterisks (**) indicate p , 0.01.
(C) Pancreatic sections from 8-wk-old mice of the indicated genotypes at 8 wk were stained with antibodies to Pdx1 (green) and insulin (red). Scale bars
represent 50 lm (top) and 10 lm (bottom).
(D) Immunostaining for p27kip1 in pancreatic islets of 8-wk-old WT, Irs2/, and Gsk-3bþ/Irs2/ mice. Hematoxylin counterstaining reveals nucleus in dark
blue (and acinar cells in light blue); p27kip1 staining is in red. Scale bars represent 50 lm.
doi:10.1371/journal.pbio.0060037.g006

that Gsk-3 activity stabilizes p27kip1 levels, suggesting a
mechanism for impairment of proliferation. The results of
these studies thus indicate that in insulin-resistant animals,
Gsk-3b impairs replication and enhances cell death, leading to
postnatal b-cell loss and diabetes.
FoxO1 and Gsk-3b are both negatively regulated targeted
proteins of the insulin/PI-3K/Akt signaling pathway. Previous
studies showed that Irs2/ mice crossed with Foxo1þ/ mice
resulted in partial correction of fed plasma glucose, b-cell
mass, and proliferation [39], along with improved Pdx1
expression. In the current study, we found that islets of
Irs2/ mice had increased Gsk-3 activity (Figure 3A and 3B),
now demonstrating that both Gsk-3 and FoxO1 signiﬁcantly
contribute to the impaired proliferation and increased
apoptosis in Irs2/ mice.
What are the mechanisms that could account for postnatal
loss of b-cell mass in the insulin-resistant models? Evidence to
date suggests that FoxO1 is contributing through impaired
PLoS Biology | www.plosbiology.org

proliferation and enhanced apoptosis via transcriptional
mechanisms, as it has been shown to repress Pdx1 transcription in insulinoma cells [39]. In non–b-cells FoxO1 has
also been shown to increase p27Kip1 expression [45]. The
results of the current studies suggest a novel mechanism for
regulation of Pdx1 and p27Kip1 levels in insulin-resistant bcells through Gsk-3b activity. In non–b-cells, the half-life (t1/2)
of p27Kip1 protein was 12 h in the absence of growth factors,
and 20 min when growth factors were restored, or when cells
were treated with Gsk-3b inhibitors [44]. Gsk-3b phosphorylated and stabilized p27Kip1, whereas Gsk-3b inhibitors
targeted p27Kip1 for proteosomal degradation. These results
suggest a possible mechanism by which Gsk-3 activity might
regulate cell proliferation in b-cells through altered p27Kip1
stability. There is substantial evidence that this mechanism is
operational in b-cells. First, p27kip1 levels were increased in
islets from Irs2/ mice (Figure 6B and 6D, and [40]), and levels
were reduced with elimination of one allele of Gsk-3b.
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The Irs2/ mice have severe impairment of the insulin
signaling PI-3K/Akt pathway, and rapidly lose b-cell mass.
Elimination of one allele of Gsk-3b in Irs2/ mice preserves
b-cell mass and, for the most part, maintains glucose
homeostasis, yet Gsk-3b is only one of many substrates
regulated by the insulin signaling pathway. For example,
Irs2/ mice have increased FoxO1 [39], and perhaps
decreased S6K levels, along with alterations in other Akt
substrates. Although the Gsk-3bþ/Irs2/ mice maintain
apparently normal b-cell mass, they are still insulin resistant,
and therefore not fully functional; they would be anticipated
to have expanded b-cell mass as shown in the Irþ/ mice
(Figure 2E). Thus Gsk-3b is only one protein among many
necessary for fully functional b-cells.
Elimination of one allele of Gsk-3b in insulin-resistant Irþ/
mice enhanced insulin sensitivity by augmenting peripheral
insulin-mediated glucose disposal, independent of effects on
hepatic glucose output (Figure 1C–1E). These results are
consistent with those in which tissue-speciﬁc knockout of
Gsk-3b in skeletal muscle enhanced insulin sensitivity (S.
Patel, B. W. Doble, K. MacAulay, E. M. Sinclair, D. J. Drucker,
and J. R. Woodgett, unpublished data). Could enhanced
peripheral insulin sensitivity by loss of one allele of Gsk-3b
account for the preservation of b-cell mass in the Irs2/ mice?
The results with conditional knockout of the Gsk-3b gene in
b-cells indicate the importance of this protein in the b-cell
with impaired insulin signaling and that under these circumstances, Gsk-3a is not playing a major role. Although the
exact contribution of Gsk-3a to b-cell function has yet to be
determined, the results of Patel et al. (S. Patel, B. W. Doble, K.
MacAulay, E. M. Sinclair, D. J. Drucker, and J. R. Woodgett,
unpublished data) and MacAulay et al. [47] emphasize the
isoform and tissue-selective effects of the two mammalian
Gsk-3s in skeletal muscle and liver.
The results of these studies now deﬁne a new, negatively
regulated substrate of the insulin signaling pathway speciﬁcally
within b-cells that when elevated, can impair replication and
increase apoptosis, resulting in postnatal loss of b-cells and
diabetes. These results thus form the rationale for developing
agents to inhibit this enzyme in obese insulin-resistant
individuals to preserve b-cells and prevent diabetes onset.

Figure 7. The Effects of b-Cell–Specific Gsk-3b Deficiency in Irs2/ Mice
(A) Islets were isolated from 6-wk-old control mice, Irs2/ mice, and
bGsk-3b/Irs2/ mice were lysed. Lysates were subjected to western
blot analysis using anti-Irs2, anti-total Gsk-3, anti-phosho glycogen
synthase, and a-tubulin. One of two independent experiments is shown.
(B) Fed glucose levels were assessed in control mice (filled triangles; n ¼
11), Irs2/ mice (filled diamonds; n ¼ 10), and bGsk-3b/ Irs2/ mice
(filled squares; n ¼ 5) at the indicated ages.
(C) Fed plasma insulin levels were assessed in control mice (filled triangles;
n ¼ 11), Irs2/ mice (filled diamonds; n ¼ 10), and bGsk-3b/ Irs2/ mice
(filled squares; n ¼ 5) at the indicated ages. Results are presented as the
mean 6 S.E.M. in the graph. A single asterisk (*) indicates p , 0.05; double
asterisks (**) indicate p , 0.01; and triple asterisks (***) indicate p , 0.001.
doi:10.1371/journal.pbio.0060037.g007

Materials and Methods
Animal production and phenotypic analysis. Generation and
genotyping of Gsk-3bþ/, Irþ/, and Irs2/ mice have been described
[23,37,38,48]. We maintained Irþ/ mice on the C57BL/6J background
and the Irs2/ mice on a mixed C57BL/6J 3 129Sv background, and
crossed them with Gsk-3bþ/ mice on the C57BL/6J 3 129Sv back
ground to obtain Gsk-3b þ/Irþ/ and Gsk-3bþ/Irs2þ/ mice on a mixed
C57BL/6J 3 129Sv background. Double-heterozygote F1 offspring
were intercrossed (Gsk-3bþ/Irs2þ/) to obtain Gsk-3bþ/Irs2/ mice.
The Gsk-3bþ/Irs2/ progeny was observed at the expected Mendelian
frequency in both instances. WT control mice have been obtained
from littermates of double-heterozygous breeding.
The generation of mice expressing a conditional allele of Gsk-3b
will be described in further detail (S. Patel, B. W. Doble, K. MacAulay,
E. M. Sinclair, D. J. Drucker, and J. R. Woodgett, unpublished data). In
brief, R1 embryonic stem (ES) cells were electroporated with a
modiﬁed Gsk-3b targeting vector whereby LoxP sites were introduced
by PCR into the intronic region ﬂanking exon 2 of Gsk-3b, and a
neomycin resistance cassette was inserted and ﬂanked by FLP
recombinase target (FRT) sites
ES cell clones that had undergone correct homologous recombination were identiﬁed by Southern blot and microinjected into C57/B6J
blastocysts. The resultant chimeric mice were crossed to C57/B6J, and
germline transmission of the Gsk-3b ﬂoxed allele was veriﬁed by PCR.
Resultant interbreeding of these mice yielded Gsk-3b ﬂoxed mice that

Second, in vitro evidence is presented showing that Gsk-3
activity regulates p27Kip1 protein stability in insulinoma cells
(Figure 8A). Third, physiological support for the conclusion
that Gsk-3 activity stabilizes p27kip1 levels in pancreatic islets
is presented (Figure 8B). In contrast to p27Kip1 protein
stabilization, Gsk-3 activity was shown to destabilize Pdx1
protein levels in insulinoma cells [46]. We have conﬁrmed this
effect of Gsk-3 activity on Pdx1 in MIN6 cells (unpublished
data), and now provide in vivo evidence that reduction of islet
Gsk-3b activity restores Pdx1 levels in islets of Gsk-3bþ/Irs2/
mice (Figure 6B and 6C).
PLoS Biology | www.plosbiology.org
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Figure 8. Effects of Inhibition of Gsk-3 Activity on Protein Stability of p27kip1
(A) MIN6 cells were pretreated with either 40 mM lithium chloride (LiCl) or 40 mM NaCl in DMEM with 15% FBS for 1 h and were cotreated with 25 lg/ml
cyclohexamide and lithium or NaCl for 4 h. The lysates were subjected to western blot analysis with anti-p27kip1, phospho-glycogen synthase, total Gsk3b, and a-tubulin. Densitometry of p27kip1 was measured and normalized over a-tubulin.
(B) Islets isolated from 16-wk-old WT mice were deprived of serum for 4 h and were incubated with no addition, or with addition of 100 nM IGF-1, or 40
mM LiCl, or both for 3 h. Lysates were then prepared from islets and were subjected to western blot analysis with anti-p27kip1, anti-phospho glycogen
synthase, anti-total Gsk-3b, and b-actin. Representative results of three independent experiments are presented. Densitometry of p27kip1 was measured
and normalized over b-actin. Mean protein levels 6 S.E.M. are summarized on the graph. A single asterisk (*) indicates p , 0.05; double asterisks (**)
indicate p , 0.01.
doi:10.1371/journal.pbio.0060037.g008
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for 4 h, were prepared. The lysates were probed with the antibodies
listed above.
Islets isolated from 16-wk-old WT mice were deprived of serum for
4 h and were incubated in the absences or presence of 10% FBS, 100
nM IGF-1, or 40 mM LiCl for 3 h. Lysates were then prepared from
islets and were subjected to western blot analysis with the antibodies
listed above.
Immune complexes were revealed using ECL Advance Western
Blot Detection kit (Amersham), and the images were acquired using a
FluoroChemi 8800 digital camera acquisition system (Alpha Innotech). Band intensities in the blots were later quantiﬁed using ImageJ
1.39j [53] and a-tubulin or b-actin bands were used to adjust for
loading differences.
Statistical analysis. Quantitative data are presented as the mean 6
the standard error of the mean (S.E.M.) from at least three
independent experiments and at least 100 islets from more than
three mice, unless indicated. We assessed interactions among
variables by two-way analysis of variance and used the Student’ ttest to compare independent means. A p-value of 0.05 was considered
statistically signiﬁcant.

were viable, healthy, born with the expected Mendelian frequency, and
expressed Gsk-3b at levels indistinguishable from WT animals.
Pancreatic b-cell–speciﬁc Gsk-3b knockout mice (bGSK-3b–/–) were
generated by breeding Gsk-3b ﬂoxed mice with mice that express the
Cre recombinase gene under the control of the promoter of the rat
insulin 2 gene [49]. To obtain bGsk-3b–/–Irs2þ/ mice, F1 offspring (Gsk3bF/þIrs2þ/) were intercrossed. They were then further intercrossed
with F2 offspring (bGsk-3b–/–Irs2þ/) to obtain bGsk-3b–/–Irs2/ mice.
Blood glucose as well as serum insulin concentrations were
determined as previously described [13]. For the glucose tolerance
test, mice were subjected to an overnight fast followed by intraperitoneal glucose injection (2.0 g/kg). Blood samples were collected
at 0, 30, 60, and 120 min after the injection. For the insulin tolerance
tests, mice were subjected to a 4-h fast followed by intraperitoneal
human regular insulin injection (0.5 U/kg). Blood samples were
collected 0, 30, 60, and 120 min after the injections. After sacriﬁcing
the mice, the pancreas was removed and weighed. All experiments were
carried out with male mice. This project was approved by the Animal
Ethics Committee of Washington University School of Medicine.
Hyperinsulinemic-euglycemic clamps. Clamp experiments were
essentially performed as previously described [50,51]. Double-lumen
catheters were placed and 3-[3H] glucose was infused to steady state.
Regular human insulin was infused at 20 mU/kg per min with 25% Dglucose to maintain the blood glucose at 120 mg/dl for at least 90 min.
The 3-[3H] glucose infusion was continued during the clamp, with
labeled glucose included in the 25% D-glucose infusion to match blood
speciﬁc activity at steady state. The rate of appearance of glucose (Ra),
equal to the rate of glucose utilization (Rd) at steady state, was
determined by dividing the infusion rate of labeled glucose by the
speciﬁc activity. Endogenous glucose production was calculated by
subtracting the cold glucose infusion rate from the clamp Rd.
Immunohistochemical and morphometric analysis of the pancreatic islets. Pancreas were isolated and ﬁxed from 8-wk-old Irs2/, Gskþ/
3b Irs2/, and Gsk-3bþ/ mice. Isolated pancreas were ﬁxed overnight in 3.7% formaldehyde at room temperature. Tissue was then
routinely processed for parafﬁn embedding, and 5-lm sections were
cut and mounted on glass slides. The sections were immunostained
with antibodies to insulin (Dako), glucagon (Sigma Aldrich), Ki67
(Zymed Laboratories/Invitrogen), Pdx-1 (Joel Habener), and p27kip1
(BD Transduction Laboratories). Histomouse-SP (Zymed Laboratories/Invitrogen) was used for secondary antibodies for brightﬁeld
microscopy and b-cell mass, whereas Cy3- or ﬂuorescein isothiocyanateconjugated (FITC) secondary antibodies (Jackson Immunoresearch) were used for ﬂuorescence microscopy. All images were
acquired on a DM4000 B microscope (Leica Microsystems). The b-cell
area was determined after the analysis of a number of random
sections stained for insulin and analyzed with NIH Image 1.38x
software [52]. The total b-cell mass was then calculated using the
following calculation: [(islet area/total pancreas area) 3 pancreas
weight]. Five pancreatic sections from each animal, including
representative sections of pancreas, and at least 100 islets per mouse
were counted. Adjacent nonoverlapping ﬁelds were analyzed to
obtain a true representation of average islet/b cell distribution
throughout the pancreas.
TUNEL staining was performed on pancreatic sections using the
ApopTag in situ apoptosis detection kit and according to the
manufacturer’s instructions (Chemicon/Milipore). At least 3,000
insulin-positive cells were counted for each mouse to assess the
percentage of TUNEL-positive cells among insulin-positive cells.
Quantitative data are obtained from at least three mice in each
group, unless indicated.
Western blotting analysis. Islet isolation were carried out as
described previously [53]. For immunoblot analysis, isolated islets
were lysed in ice-cold cell lysis buffer consisting of 50 mM HEPES (pH
7.5), 1% (v/v) Nonidet P-40, 2 mM activated sodium orthovanadate,
100 mM sodium ﬂuoride, 10 mM sodium pyrophosphate, 4 mM
EDTA, 1 mM phenylmethylsulfonyl ﬂuoride, 1 lg/ml leupeptin, and 1
lg/ml aprotinin, then passed through a syringe ten times; particulate
material was removed by centrifugation (10,000 3 g; 10 min; 4 8C).
The supernatant was collected. The extracts (50 lg of total protein)
were subjected to immunoblot analysis with antibodies to Gsk-3b
phosphorylated on Ser9, Akt phosphorylated on Ser473, Akt
phosphorylated on Thr308, total Akt, total Gsk-3a/b (Cell Signaling),
total Gsk-3b (BD Transduction Laboratories), and glycogen synthase
phosphorylated on Ser 641 and 645 (Biosource/Invitrogen), Irs2
(Upstate), Pdx1 (Santa Cruz SC14664), p27kip1 (BD Transduction
Laboratories), a-tubulin, and b-actin (Sigma-Aldrich).
For immunoblot analysis with mouse insulinoma MIN6 cells,
lysates of MIN6 cells treated with either 40 mM lithium or 40 mM
NaCl for 1 h, then cotreated with 25 lg/ml cyclohexamide and lithium
PLoS Biology | www.plosbiology.org
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Figure S1. The Effects of Haploinsufﬁciency for Gsk-3b on
Carbohydrate Metabolism in Irþ/ Mice at 8–10 wk of Age
(A) Fasting and fed glucose of indicated genotypes at (8–10 wk of age).
(B) Fasting and fed insulin levels (8–10 wk of age).
(C) Intraperitoneal glucose tolerance tests were performed on
overnight-fasted male Irþ/ mice at 8 wk of age and Gsk-3bþ/Irþ/
mice at 8 wk of age after intraperitoneal injection of D-glucose (2 g/kg
of body weight; n ¼ 6). Glucose levels were assessed at the indicated
time intervals. Results are presented as the mean 6 S.E.M. in the
graph. A single asterisk (*) indicates p , 0.05.
Found at doi:10.1371/journal.pbio.0060037.sg001 (266 KB PDF).
Figure S2. The Effects of Haploinsufﬁciency for Gsk-3b on
Carbohydrate Metabolism in Irs2/ Mice at 24 wk of Age
(A) Body weight in mice, either WT (n ¼ 10) or Gsk-3bþ/Irs2/ (n ¼ 13).
(B) Fed glucose in mice, either WT (n ¼ 10) or Gsk-3bþ/Irs2/ (n ¼ 13).
(C) Fed insulin levels in mice, either WT (n ¼ 7) or Gsk-3bþ/Irs2/ (n ¼
8). Results are presented as the mean 6 S.E.M. in the graph. A single
asterisk (*) indicates p , 0.05.
Found at doi:10.1371/journal.pbio.0060037.sg002 (231 KB PDF).
Figure S3. The Effects of Haploinsufﬁciency for Gsk-3b on Apoptosis
in the Islets of Irs2/ Mice
Pancreatic sections from 8-wk-old mice of indicated genotypes were
subjected to TUNEL assay. Arrowheads indicate apoptotic nuclei.
Scale bar represents 50 lm.
Found at doi:10.1371/journal.pbio.0060037.sg003 (7.8 MB PDF).
Table S1. Fasting Blood Glucose Concentration at 6 and 8 wk of Age
in Either WT, Gsk-3bþ/, Irs2/, or Gsk-3bþ/Irs2/ Mice
Fasting glucose in mice, either WT (n ¼ 10), Gsk-3bþ/ (n ¼ 9), Irs2/ (n
¼ 15), or Gsk-3bþ/Irs2/ (n ¼ 12) were determined after an overnight
fast at 6 and 8 wk of age. Mean values 6 S.E.M. are summarized in the
table. Triple asterisks (***) indicate p , 0.001.
Found at doi:10.1371/journal.pbio.0060037.st001 (216 KB PDF).
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